RxDoctor Payments Data

Shannon Michaud

Adult Health · Prescott, AZNPI 1093073041

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,530 of the $2,131 with a category attached, or 71.8%. 11 manufacturers reported payments, led by Boston Scientific at 49.5% of the total. Reporting peaked in 2024 at $1,514 and has fallen 93.3% since, to $101 in 2025.

$2,131in general payments, 2019–2025

Across 29 payments — averaging $73.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Edwards Lifesciences$742
  • Novartis$141
  • Amgen$59
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$42
  • AbbVie$19
  • plus $75 from 5 others

What the payments were for

  • Travel & lodging$60228%
  • Food & beverage$1,53072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,131 in reported general payments places this provider in the 80th percentile of 314 adult health providers in Arizona.

See all adult health providers in Arizona

Medicare billing

Part B allowed, 2024
$52,008
Medicare patients
349
Services billed
660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$78,441
EntrestoSacubitril/Valsartan41$50,898
JardianceEmpagliflozin22$24,653
BrilintaTicagrelor20$20,549
Nebivolol Hcl24$1,738
Valsartan47$1,605
Ezetimibe52$1,425
Prasugrel Hcl11$1,361
ClopidogrelClopidogrel Bisulfate109$1,334
Metoprolol Succinate70$951
Atorvastatin Calcium93$814
Enoxaparin Sodium13$782
Losartan Potassium96$708
Amiodarone Hcl17$662
Carvedilol77$580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$141$50,89841 claims
AstraZenecaBrilinta$13$20,54920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 314 adult health providers in Arizona.

Other adult health in Prescott

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →